Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential

One study investigator pointed to the data for ADP-A2M4 as indicating much greater efficacy in the rare cancer than existing therapy options, while another said it demonstrated cell therapies' potential outside of the blood cancer space.